ArticleBMC nephrology2026
Impact of eGFR-based physician-visit recommendations on CKD-related clinical practices following health screening: a regression discontinuity study.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond urinalysis: a review of life-course chronic kidney disease screening across health examination systems in Japan.Clinical and experimental nephrology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a global health issue, yet most patients remain undiagnosed. It is unclear whether recommendations for physician visit based on estimated glomerular filtration rate (eGFR) promote appropriate clinical practices among individuals with undiagnosed CKD. We aimed to investigate the impact of eGFR-based physician-visit recommendations on CKD-related clinical practices among health insurance beneficiaries who participated in annual health screening.
methodsWe used health screening and administrative data of Japanese adults aged 40–74 years who underwent screening between April 2022 and March 2023. Participants were mailed their results along with eGFR-based recommendations for physician visits when eGFR was below designated cutoffs. To evaluate the impact of these recommendations on the receipt of guideline-concordant CKD practices within 1 year, we used a regression discontinuity model, treating eGFR as the running variable with a cutoff of 60 mL/min/1.73 m2. Our primary outcomes were serum creatinine (sCr) measurement and CKD diagnosis, which substantiate an actual physician visit. Secondary outcomes included urinary protein assessment and nutritional guidance, both essential for appropriate CKD management.
resultsWe included 206,222 participants (62.2% males; age 52 ± 7 years). The 60 mL/min/1.73 m2 cutoff for physician-visit recommendations was associated with modest increases in sCr measurement (3.20%; 95% confidence interval [CI], 0.73 to 5.67; p = 0.01) and CKD diagnosis (0.76%; 95% CI, 0.10 to 1.41; p = 0.02). However, no significant associations were observed for the dipstick urine protein test (0.28%; 95% CI, −1.63 to 2.20; p = 0.77), urinary protein-creatinine ratio (0.02%; 95% CI, −0.46 to 0.49; p = 0.95), and nutritional guidance (−4.30 × 10−5 %; 95% CI, −0.48 to 0.49; p = 0.99).
conclusionsThe cutoff of 60 mL/min/1.73 m2 was associated with modest increases in physician visits, as substantiated by sCr measurement and CKD diagnosis. However, it was not associated with enhanced quality of CKD care, including urine testing and nutritional guidance, which are essential components of appropriate CKD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.